About Addex Therapeutics Ltd
https://www.addextherapeutics.comAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors.
CEO
Timothy Mark Dyer
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 12, 2020
Method of going public Dual Listing
Full time employees 2
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-10-23 | Reverse | 1:20 |
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 4
Overall Score 2
Price Target
Target High $30
Target Low $30
Target Median $30
Target Consensus $30
Market Cap $5.15 M
52w High $12.05
52w Low $6.51
P/E -0.91
Volume 1.37K
Outstanding Shares 660.58K
About Addex Therapeutics Ltd
https://www.addextherapeutics.comAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $29.72K ▼ | $725.9K ▲ | $-1.58M ▲ | -5.31K% ▼ | $-1.2 ▲ | $-1.57M ▲ |
| Q2-2025 | $36.38K ▲ | $534.82K ▼ | $-1.84M ▼ | -5.06K% ▼ | $-2.56 ▼ | $-1.96M ▼ |
| Q1-2025 | $0 ▼ | $606.26K ▲ | $-1.47M ▼ | 0% ▲ | $-1.8 ▼ | $-1.47M ▼ |
| Q4-2024 | $1.51K ▼ | $447.13K ▼ | $-1.21M ▲ | -79.96K% ▼ | $-1.45 ▲ | $-1.16M ▲ |
| Q3-2024 | $53.84K | $676.04K | $-1.53M | -2.84K% | $-1.88 | $-1.47M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.19M ▼ | $7.33M ▼ | $1.37M ▲ | $5.96M ▼ |
| Q2-2025 | $2.3M ▼ | $8.51M ▼ | $1.29M ▲ | $7.21M ▼ |
| Q1-2025 | $2.83M ▼ | $9.48M ▼ | $1.19M ▲ | $8.3M ▼ |
| Q4-2024 | $3.35M ▼ | $10.68M ▼ | $1M ▼ | $9.68M ▼ |
| Q3-2024 | $3.35M | $12.17M | $1.11M | $11.06M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.58M ▲ | $-533.2K ▼ | $60.07K ▲ | $361.01K ▼ | $-113.79K ▲ | $-533.2K ▼ |
| Q2-2025 | $-1.84M ▼ | $-419.84K ▲ | $-737.36K ▼ | $649.19K ▲ | $-524.49K ▼ | $-419.84K ▲ |
| Q1-2025 | $-1.47M ▼ | $-598.71K ▼ | $0 ▲ | $97.99K ▲ | $-516.25K ▼ | $-598.71K ▼ |
| Q4-2024 | $-1.21M ▲ | $-23.56K ▲ | $-15.9K ▼ | $-1.72K ▼ | $-7.44K ▲ | $-23.56K ▲ |
| Q3-2024 | $-1.53M | $-398.58K | $-5.84K | $-494 | $-438.6K | $-399.86K |
CEO
Timothy Mark Dyer
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 12, 2020
Method of going public Dual Listing
Full time employees 2
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-10-23 | Reverse | 1:20 |
Ratings Snapshot
Rating : C+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 4
Overall Score 2
Price Target
Target High $30
Target Low $30
Target Median $30
Target Consensus $30